Impact of Prostatitis and Benign Prostate Hyperplasia (BPH) on risk factors for Prostate Cancer

Principal Investigator

Name
Andrew Marks

Degrees
M.S., M.A.

Institution
Claremont Graduate University

Position Title
Data Scientist

Email
andrew.marks@cgu.edu

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-641

Initial CDAS Request Approval
Jul 17, 2020

Title
Impact of Prostatitis and Benign Prostate Hyperplasia (BPH) on risk factors for Prostate Cancer

Summary
Examine the relationship between previous health issues related to the prostate and the risk of prostate cancer (PCa) in patients. Specifically, is a patient history of an enlarged prostate (Benign Prostate Hyperplasia or BPH) or prostatitis associated with higher occurrences of PCa, how does mortality differ for patients with this medical history, should screening such as prostate-specific antigen (PSA) begin earlier for men who a history of these prostate related health issues.

Aims

Is there a higher occurrence of PCa in men with previous prostate related health issues?
Is there a difference in mortality rates for patients with previous prostate related health issues?
Is there a difference in severity in men with previous prostate related health issues?
What are the mortality differences in early detection by looking at ages of when screening takes place?

Collaborators

Andrew Marks, Claremont Graduate University